| 证券代码：603707 | 证券简称：健友股份 | 公告编号：2023-076 | | --- | --- | --- | | 债券代码：113579 | 债券简称：健友转债 | | 南京健友生化制药股份有限公司 关于召开 2024 年第一次临时股东大会的通知 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： (一) 股东大会类型和届次 一、 召开会议的基本情况 2024 年第一次临时股东大会 召开的日期时间：2024 年 1 月 5 日 14 点 00 分 召开地点：南京市高新开发区学府路 16 号公司会议室 股东大会召开日期：2024年1月5日 本次股东大会采用的网络投票系统：上海证券交易所股东大会网络投票 系统 (二) 股东大会召集人：董事会 (三) 投票方式：本次股东大会所采用的表决方式是现场投票和网络投票相结 合的方式 (四) 现场会议召开的日期、时间和地点 (五) 网络投票的系统、起止日期和投票时间。 1、 各议案已披露的时间和披露媒体 网络投票系统：上海证券交易所股东大会网络投票系统 网络投票起 ...

| 证券代码：603707 | 证券简称：健友股份 | 公告编号：2023-079 | | --- | --- | --- | | 债券代码：113579 | 债券简称：健友转债 | | 南京健友生化制药股份有限公司 关于签字会计师变更的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 公司于 2023 年 12 月 19 日收到公证天业发来的《关于变更南京健友生化制 药股份有限公司签字注册会计师及项目质量控制复核人的说明函》。现将相关情 况公告如下： 项目质量控制复核人薛敏女士：2000 年 12 月成为注册会计师，1997 年 12 月开始从事上市公司审计，1997 年 12 月开始在公证天业执业；近三年复核的上 市公司有航亚科技（688510）、贝斯特（300580）、太极实业（600667）等，具 有证券服务业务从业经验，具备相应的专业胜任能力。 娄新洁女士、虞哲先生以及薛敏女士均不存在违反《中国注册会计师职业道 德守则》对独立性要求的情形，近三年未因执业行为受到刑事处罚，未受到证监 会及其派出机构、行业主管 ...

证券代码：603707 证券简称：健友股份 编号：2023-001 债券 代码：113579 债券简称：健友转债 南京健友生化制药股份有限公司 投资者关系活动记录表 投资者关系 ■特定对象调研 □分析师会议□媒体采访 □业绩说明会 □新闻发布会 □路演活动 □现场参观 活动类别 □其他（请文字说明其他活动内容） 公司名称 姓名 公司名称 姓名 公司名称 姓名 兴业证券 黄翰漾 招银理财 熊超逸 富国基金 孙笑悦 鲍尔赛嘉 林炎 兴业证券 杨希成 招银理财 郝雪梅 广发资管 徐默凡 长盛基金 郝征 德汇集团 蔡荣转 HBM 国君资管 吴佳玮 中泰资管 张闻熙 郭牧青 Partners 鲸域资产 万巍 华夏久盈 张伟光 富国基金 周文波 凯丰投资 薛良辰 财通基金 沈犁 峰境基金 魏磊 蜂巢基金 赵花琴 银河基金 施文琪 中海基金 陈玮 汇安基金 高苏 Point72 李大蔚 兴业证券 邹文凯 参与单位名 万纳资产 王立立 东证创金 刘梦杨 远信资本 王楠 ...

Financial Performance - The company's revenue for Q3 2023 was ¥838,185,440.57, representing a decrease of 4.28% compared to the same period last year[3]. - The net profit attributable to shareholders for Q3 2023 was ¥214,806,533.63, down 26.69% year-over-year[3]. - The net profit excluding non-recurring gains and losses for Q3 2023 was ¥211,955,121.56, a decrease of 25.49% compared to the same period last year[3]. - Basic earnings per share for Q3 2023 were ¥0.13, down 27.78% year-over-year[4]. - Diluted earnings per share for Q3 2023 were ¥0.14, a decrease of 22.22% compared to the same period last year[4]. - The net profit for Q3 2023 was CNY 839,329,356.88, a decrease of 7.2% compared to CNY 904,845,162.80 in Q3 2022[24]. - The total profit for Q3 2023 was CNY 957,050,998.20, compared to CNY 1,050,013,815.96 in Q3 2022, reflecting a decline of 8.8%[24]. - The total comprehensive income for Q3 2023 was CNY 843,990,879.46, compared to CNY 905,879,986.32 in Q3 2022, reflecting a decrease of 6.8%[25]. Cash Flow and Assets - The cash flow from operating activities for the year-to-date period increased by 85.46%, totaling ¥1,171,194,935.25[3][8]. - Cash flow from operating activities for the first three quarters of 2023 was CNY 1,171,194,935.25, significantly higher than CNY 631,513,877.83 in the same period of 2022[27]. - The cash and cash equivalents increased to approximately ¥2.11 billion as of September 30, 2023, compared to ¥1.39 billion at the end of 2022, representing a growth of 51.8%[18]. - The company's inventory stood at approximately ¥5.53 billion as of September 30, 2023, slightly down from ¥5.62 billion at the end of 2022, indicating a decrease of 1.6%[18]. - The total assets as of the end of the reporting period were ¥11,122,721,263.40, an increase of 11.11% from the end of the previous year[4]. - The total assets of the company reached approximately ¥11.12 billion as of September 30, 2023, compared to ¥10.01 billion at the end of 2022, marking an increase of 11.1%[20]. Shareholder Information - Shareholders' equity attributable to shareholders was ¥6,830,234,621.13, reflecting a growth of 10.69% year-over-year[4]. - The total number of ordinary shareholders at the end of the reporting period was 24,366[9]. - The top shareholder, Xie Juhua, holds 27.20% of the shares, totaling 439,682,951 shares[9]. Business Operations and Strategy - The formulation business accounted for 74.16% of total revenue, while the API business contributed 21.82%[13]. - The company has established a stable market share for certain products in the U.S. market, leveraging its sales and operational channels through its subsidiary Meitheal[13]. - The company is focusing on high-end formulations, with a significant shift from API to sterile injectables, reducing the API revenue share from over 60% in 2019 to less than 30% in 2022[13]. - The CDMO business revenue has declined year-over-year, indicating that the business model is still in its early stages[13]. - The company is actively expanding its international market presence, particularly in the U.S. and Europe, to enhance its competitive edge[13]. - The company is collaborating with top international teams for drug development, particularly in the orphan drug XTMAB project, to explore global commercialization opportunities[14]. - The company aims to enhance its global market presence and improve the competitiveness of its product pipeline through strategic partnerships and collaborations[14]. - The company plans to enhance its R&D, registration, production, quality, and marketing capabilities to expand its product pipeline and market presence both domestically and internationally[15]. - The company aims to improve operational efficiency by shortening sales cycles to mitigate the impact of exchange rate fluctuations on business performance[15]. - The company reported a total operating revenue of approximately ¥3.14 billion for the first three quarters of 2023, an increase of 10.2% compared to ¥2.85 billion in the same period of 2022[22]. - The total operating costs for the first three quarters of 2023 were approximately ¥2.18 billion, up from ¥1.82 billion in the same period of 2022, reflecting a year-on-year increase of 20%[22]. Research and Development - R&D expenses for the period reached RMB 61.99 million, an increase of 11.38% compared to the same period last year[14]. - The company has acquired over 10 ANDA approvals from partners, enhancing its platform capabilities for sterile injectables[14]. - Research and development expenses increased to CNY 212,803,589.87 in Q3 2023, up 31.7% from CNY 161,520,139.29 in Q3 2022[24]. Foreign Exchange and Financial Adjustments - The company experienced a foreign exchange loss of approximately ¥12.28 million in Q3 2023 due to the appreciation of the RMB, which significantly impacted net profit compared to the previous year[15]. - The company reported a net profit decline due to foreign exchange losses and increased operational costs, emphasizing the need for strategic adjustments in response to market pressures[15]. - Other comprehensive income after tax for Q3 2023 was CNY 4,661,522.58, compared to CNY 1,034,823.52 in Q3 2022, showing an increase of 351.5%[25]. - The company recorded a financial expense of CNY -65,049,275.88 in Q3 2023, an improvement from CNY -173,863,661.78 in Q3 2022[24]. - The net cash flow from financing activities was -$666.21 million, contrasting with a positive $357.36 million in the previous year[29]. - The impact of exchange rate changes on cash and cash equivalents was -$59.92 million, compared to a positive impact of $28.57 million in the previous year[29].

| 证券代码：603707 | 证券简称：健友股份 | 公告编号：2023-073 | | --- | --- | --- | | 债券代码：113579 | 债券简称：健友转债 | | 南京健友生化制药股份有限公司 关于召开 2023 年第三季度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： https://roadshow.sseinfo.com/） 南京健友生化制药股份有限公司（以下简称"公司"）已于 2023 年 10 月 28 日发布公司 2023 年三季度报告，为便于广大投资者更全面深入地了解公司 2023 年三季度经营成果、财务状况，公司计划于 2023 年 11 月 13 日上午 09:00-10:00 举行 2023 年第三季度业绩说明会，就投资者关心的问题进行交流。 一、 说明会类型 本次投资者说明会以网络互动形式召开，公司将针对 2023 年三季度的经营 成果及财务指标的具体情况与投资者进行互动交流和沟通，在信息披露允许的范 围内就投资者普遍关注的问题进行回答。 会议召开 ...

| 证券代码：603707 | 证券简称：健友股份 | 公告编号：2023-071 | | --- | --- | --- | | 债券代码：113579 | 债券简称：健友转债 | | 南京健友生化制药股份有限公司 许可协议暨关联交易的进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 一、本次交易概述 2023 年 6 月 27 日,南京健友生化制药股份有限公司（以下简称"公司""健 友股份"）召开第五届董事会第二次会议，审议通过了《关于公司子公司与 Xentria 签署许可协议暨关联交易的议案》，关联董事唐咏群、谢菊华回避表决， 独立董事发表了事前认可意见和同意的独立意见。 2023 年 7 月 18 日，南京健友生化制药股份有限公司（以下简称"公司""健 友股份"） 召开 2023 年第二次临时股东大会，审议通过了《关于公司子公司与 Xentria 签署许可协议暨关联交易的议案》，关联股东谢菊华、唐咏群回避表决。 公司的全资子公司香港健友实业有限公司（以下简称"香港健友""被许可 方代表"）及香港健友控股子 ...

| 证券代码：603707 | 证券简称：健友股份 | 公告编号：2023-070 | | --- | --- | --- | | 债券代码：113579 | 债券简称：健友转债 | | 南京健友生化制药股份有限公司 关于"健友转债"转股结果暨股份变动的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 自 2021 年 7 月 15 日起，健友转债转股价格变为 32.20 元/股。因公司实施 2021 年限制性股票激励计划预留授予，自 2022 年 6 月 10 日起，健友转债转股价格变 为 32.19 元/股。因公司实施 2021 年年度权益分派，自 2022 年 7 月 11 日起，健 友转债转股价格变为 24.65 元/股。因公司实施 2022 年年度权益分派，于 2023 年 7 月 7 日起，健友转债转股价格变为 24.54 元/股。 重要内容提示： 转股情况： 截至 2023 年 9 月 30 日，累计已有人民币 690,000 元"健友转债"转为公司 普通股，累计转股股数 16,853 股，占转股前公司 ...

| 股票代码：603707 | 股票简称：健友股份 公告编号：2023-069 | | --- | --- | | 债券代码：113579 | 债券简称：健友转债 | 南京健友生化制药股份有限公司 关于不向下修正"健友转债"转股价格的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 1、公司于2020年7月10日起因实施2020年限制性股票激励计划，"健友转债" 的转股价格由54.97元/股调整为54.96元/股。具体内容详见公司2020年7月10日披露 的《南京健友生化制药股份有限公司关于"健友转债"转股价格调整的公告》（公 告编号：2020-061）。 2、公司于2020年7月23日起因实施2019年年度利润分配方案，"健友转债"的 转股价格由54.96元/股调整为42.05元/股。具体内容详见公司2020年7月17日披露的 《南京健友生化制药股份有限公司关于"健友转债"转股价格调整的提示性公告》 （公告编号：2020-070）。 3、公司于2021年6月25日起因实施2021年限制性股票激励计划，"健友转债" ...

| 证券代码：603707 | 证券简称：健友股份 | 公告编号：2023-068 | | --- | --- | --- | | 债券代码：113579 | 债券简称：健友转债 | | 南京健友生化制药股份有限公司 关于"健友转债"预计满足 转股价格修正条款的提示性公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 一、可转债的发行上市概况 经中国证券监督管理委员会《关于核准南京健友生化制药股份有限公司公开 发行可转换公司债券的批复》（证监许可[2020]603 号）核准，南京健友生化制 药股份有限公司（以下简称"公司"）公开发行了 5,031,900 张可转换公司债券 （以下简称"可转债"或"健友转债"），每张面值人民币 100 元，发行总额人 民币 5.0319 亿元，本次可转债存续期限为发行之日起六年，即自 2020 年 4 月 23 日至 2026 年 4 月 22 日。 1、可转债转股价格修正条款 （1）修正权限与修正幅度 在本次可转债存续期间，当公司股票在任意连续三十个交易日中至少有十五 个交易日的收盘价 ...

Financial Performance - Revenue for the first half of 2023 reached RMB 2,303,732,565.40, a year-on-year increase of 16.63%[17] - Net profit attributable to shareholders of the listed company was RMB 624,500,188.97, up 1.70% compared to the same period last year[17] - Net cash flow from operating activities increased by 26.42% to RMB 630,364,246.90[17] - Basic earnings per share increased by 2.63% to 0.39 yuan per share compared to the same period last year[18] - Weighted average return on equity decreased by 1.23 percentage points to 9.63%[18] - Non-recurring gains and losses amounted to 13,173,527.77 yuan, including government subsidies of 15,247,914.63 yuan[21][22] - The company achieved a revenue of 2.30 billion yuan in the first half of 2023, a year-on-year increase of 16.63%, with overseas sales accounting for 73.11% of total revenue at 1.68 billion yuan, and domestic sales at 619 million yuan, accounting for 26.89%[39] - Net profit attributable to the parent company in the first half of 2023 was 624.50 million yuan, a year-on-year increase of 1.70%, driven by growth in the company's formulation sales[39] - The company's U.S. subsidiary, Meitheal, achieved sales revenue exceeding 800 million yuan in the first half of 2023, a year-on-year increase of 49.70%[40] - The company's CDMO business revenue grew by over 40% in the first half of 2023, driven by strategic collaborations with global clients[40] - The company achieved a revenue of 2.30 billion yuan in the first half of 2023, a year-on-year increase of 16.63%, with a net profit of 624.50 million yuan, up 1.70% year-on-year[62] - R&D investment in the reporting period was 163.52 million yuan, a year-on-year increase of 24.17%, with a strong R&D team of over 500 people[63] - Revenue increased by 16.63% year-on-year to RMB 2.30 billion in the first half of 2023[69] - R&D expenses grew by 42.46% year-on-year to RMB 150.81 million, reflecting increased investment in innovation[69] - Net profit attributable to the parent company's shareholders was 624,500,188.97 RMB in the first half of 2023, a 1.7% increase from 614,035,642.75 RMB in the same period of 2022[181] - Basic earnings per share (EPS) for the first half of 2023 was 0.39 RMB, compared to 0.38 RMB in the same period of 2022[182] - Total comprehensive income for the first half of 2023 was 629,782,766.18 RMB, a 3.0% increase from 611,113,416.38 RMB in the same period of 2022[182] - Sales expenses rose by 21.4% to 261,555,451.30 RMB in the first half of 2023, compared to 215,454,959.30 RMB in the same period of 2022[178] - Financial expenses showed a net income of 85,700,841.49 RMB in the first half of 2023, compared to 69,193,979.94 RMB in the same period of 2022[178] - The company's total profit for the first half of 2023 was 738,348,951.76 RMB, a 3.2% increase from 715,422,314.44 RMB in the same period of 2022[180] - Income tax expenses increased by 11.7% to 113,834,452.06 RMB in the first half of 2023, compared to 101,951,732.21 RMB in the same period of 2022[180] - Comprehensive income for the first half of 2023 was RMB 510,085,407.48, compared to RMB 606,570,546.08 in the same period last year[185] - Cash flow from operating activities in the first half of 2023 was RMB 630,364,246.90, an increase from RMB 498,607,712.27 in the same period last year[187] - Cash received from sales of goods and services in the first half of 2023 was RMB 2,233,827,146.83, slightly up from RMB 2,178,973,884.58 in the same period last year[186] - Cash paid for goods and services in the first half of 2023 was RMB 1,189,538,431.81, compared to RMB 1,165,380,748.61 in the same period last year[186] - Cash flow from investing activities in the first half of 2023 was negative RMB 37,997,140.78, an improvement from negative RMB 511,030,540.94 in the same period last year[187] - Cash flow from financing activities in the first half of 2023 was negative RMB 298,667,663.85, compared to positive RMB 460,818,279.85 in the same period last year[188] - Net increase in cash and cash equivalents in the first half of 2023 was RMB 307,213,181.99, down from RMB 460,170,306.18 in the same period last year[188] - Cash received from tax refunds in the first half of 2023 was RMB 133,893,037.17, slightly down from RMB 144,194,652.57 in the same period last year[186] - Cash paid to employees in the first half of 2023 was RMB 194,191,605.46, up from RMB 148,338,042.47 in the same period last year[186] - Cash paid for taxes in the first half of 2023 was RMB 178,577,981.96, down from RMB 225,256,986.06 in the same period last year[186] - Net cash flow from investment activities was -36.65 million yuan, compared to 27.25 million yuan in the same period last year[190] - Net cash flow from financing activities was -125.01 million yuan, compared to -67.19 million yuan in the same period last year[190] - The net increase in cash and cash equivalents was 99.64 million yuan, compared to 259.20 million yuan in the same period last year[190] - The total comprehensive income for the period was 629.78 million yuan[192] - The company allocated 185.91 million yuan for profit distribution to shareholders[192] - The total owner's equity at the end of the period was 6.61 billion yuan, an increase from 6.17 billion yuan at the beginning of the period[194] - The company's capital reserve decreased by 3.11 million yuan during the period[192] - The company's undistributed profit increased by 438.59 million yuan during the period[192] - The company's special reserve increased by 71,567.71 yuan during the period[194] - The company's total liabilities and owner's equity at the end of the period was 6.61 billion yuan[194] - The company's total comprehensive income for the first half of 2023 was RMB 607,000,464.30[196] - The company allocated RMB 186,585,548.70 for profit distribution to shareholders[197] - The company's total owner's equity at the end of the period was RMB 5,858,103,612.41[198] - The company's capital reserve increased by RMB 11,928,122.64 during the period[196] - The company's undistributed profit decreased by RMB 7,035,178.45[196] - The company's special reserve increased by RMB 4,116,209.04[198] - The company's total owner's equity at the beginning of the period was RMB 5,402,757,039.30[196] - The company's capital stock increased by RMB 303,438.00[196] - The company's other comprehensive income decreased by RMB 196.10[196] - The company's total owner's equity increased by RMB 455,346,573.11 during the period[196] Assets and Liabilities - Total assets as of the end of the reporting period were RMB 11,095,253,855.79, a 10.84% increase from the end of the previous year[17] - Equity attributable to shareholders of the listed company grew by 7.22% to RMB 6,616,095,822.22[17] - Cash and cash equivalents increased by 26.13% to 1,751,303,798.14 yuan, accounting for 15.78% of total assets[72] - Trading financial assets surged by 36,076.92% to 470,300,000.00 yuan due to increased financial product purchases[72] - Accounts receivable increased by 386.68% to 107,117,814.94 yuan, driven by higher receivables from bills[72] - Prepayments rose by 260.53% to 90,370,653.36 yuan due to increased advance payments for goods[72] - Other receivables grew by 21.42% to 293,760,741.65 yuan, mainly due to increased cooperation funds from Europe and the US[72] - Fixed assets increased by 29.03% to 1,200,956,552.04 yuan, primarily due to the transfer of construction in progress to fixed assets[72][73] - Construction in progress decreased by 92.77% to 18,119,509.44 yuan, as projects were transferred to fixed assets[73] - The company's monetary funds increased to 1,751,303,798.14 yuan as of June 30, 2023, compared to 1,388,512,343.62 yuan at the end of 2022[167] - The company's total assets reached 11,095,253,855.79 yuan as of June 30, 2023, up from 10,010,102,945.14 yuan at the end of 2022[169] - The company's short-term borrowings increased to 2,251,789,666.36 yuan as of June 30, 2023, compared to 1,956,863,361.92 yuan at the end of 2022[169] - The company's accounts receivable increased to 1,009,863,891.94 yuan as of June 30, 2023, up from 952,098,814.39 yuan at the end of 2022[167] - The company's inventory decreased slightly to 5,555,576,976.64 yuan as of June 30, 2023, compared to 5,615,601,457.76 yuan at the end of 2022[168] - The company's fixed assets increased to 1,200,956,552.04 yuan as of June 30, 2023, up from 930,727,070.81 yuan at the end of 2022[168] - The company's total current liabilities increased to 3,340,928,333.11 yuan as of June 30, 2023, compared to 2,704,653,975.08 yuan at the end of 2022[169] - The company's development expenditure increased to 107,377,228.39 yuan as of June 30, 2023, up from 93,236,418.69 yuan at the end of 2022[168] - The company's total non-current assets reached 1,773,423,903.42 yuan as of June 30, 2023, compared to 1,716,038,381.10 yuan at the end of 2022[169] - Total liabilities increased to 4,482,609,220.14 RMB, up from 3,842,932,928.85 RMB in the previous period[170] - Total owner's equity (or shareholder's equity) reached 6,612,644,635.65 RMB, compared to 6,167,170,016.29 RMB previously[171] - Monetary funds increased to 184,669,804.14 RMB from 104,262,654.92 RMB[172] - Accounts receivable rose to 1,455,326,689.74 RMB from 1,200,080,987.96 RMB[172] - Inventory decreased slightly to 4,868,512,114.20 RMB from 4,987,456,425.34 RMB[172] - Total assets amounted to 8,557,447,770.81 RMB, up from 8,427,634,697.16 RMB[173] - Short-term borrowings decreased significantly to 280,957,623.00 RMB from 723,286,608.02 RMB[173] - Long-term borrowings remained stable at 500,000,000.00 RMB[174] - Total owner's equity (or shareholder's equity) increased to 6,152,857,564.88 RMB from 5,827,080,304.22 RMB[175] Product Portfolio and Market Expansion - The company has 86 overseas drug registration certificates and 26 Chinese drug registration certificates[26] - The company's product pipeline includes low molecular weight heparin preparations, anti-tumor preparations, and other high-value-added sterile injections[26] - The company's heparin sodium injection is approved in the US for anticoagulation and antithrombosis[27] - Enoxaparin sodium injection is approved in multiple countries including the US, UK, Germany, and Canada for the prevention of venous thromboembolism[27] - The company's dalteparin sodium injection is approved in China for the treatment of acute deep vein thrombosis and prevention of thrombosis related to surgery[27] - The company's nadroparin calcium injection is approved in China for the prevention of thrombosis and treatment of deep vein thrombosis[27] - The company's atracurium besylate injection is approved in the US for skeletal muscle relaxation during general anesthesia[27] - The company's product portfolio includes 50 injectable drugs, with 38 approved in the US market and 12 in the Chinese market[29][30][31][32] - Key products include Bendamustine Hydrochloride for Injection (used in the treatment of chronic lymphocytic leukemia and non-Hodgkin's lymphoma) and Mitomycin for Injection (used in the treatment of gastric cancer, lung cancer, breast cancer, etc.)[29][31] - The company is expanding its presence in the European and global markets, particularly with the registration of enoxaparin formulations in more countries[32] - The company maintains long-term stable supply relationships with major global heparin preparation manufacturers, including Pfizer, Gland, and Sanofi[32] - Heparin API business serves as a cash flow provider and foundation for the company's sterile injectable domestic and international expansion[32] - The company obtained multiple drug registration approvals, including Niraparib Injection, Rocuronium Bromide Injection, Bendamustine Hydrochloride for Injection, and Plerixafor Injection, further enriching its product pipeline[39] - The company's CDMO business focuses on providing differentiated biopharmaceutical CDMO services in regulated markets, leveraging global regulatory experience to capture higher-value service revenues[33] - The company established a Biopharmaceutical Division with platforms for protein design, drug delivery systems, molecular biology, and cell biology to enhance innovation capabilities[34] - The company's sterile injection production lines are certified by the U.S. FDA and comply with GMP and cGMP standards, ensuring product quality and safety[36] - The company's domestic formulation sales benefited from the centralized procurement policy, with products like Enoxaparin Sodium Injection and Nadroparin Calcium Injection winning bids in the 8th national drug procurement round[40] - The company's global CDMO business targets sterile injection R&D and production, serving global pharmaceutical companies and domestic innovators with a focus on expanding market demand and reducing costs[38] - The company's products are primarily focused on the anticoagulant and oncology markets, which have significant growth potential[45] - The company provides CDMO services to global and domestic pharmaceutical companies, leveraging advanced process R&D capabilities and production facilities[48] - The company has over 500 R&D personnel, including more than 80 with master's or doctoral degrees, and collaborates with R&D teams in the US and Israel[54] - The company operates four R&D centers in Nanjing, Chengdu, the US, and Israel, focusing on nucleic acid-based therapies, monoclonal antibody development, biopharmaceutical innovation, and clinical research respectively[54] - The company has established a peptide drug R&D platform using solid-phase synthesis technology, covering anticoagulation, reproductive, endocrine, and rare disease biologics[55] - The company has developed advanced complex formulation platforms, including sustained-release injections, liposomes, and auto-injector technologies[55] - The company has a strong track record of obtaining ANDA approvals, ranking first among domestic peers in the number of ANDA approvals[56] - The company has successfully launched generic drugs before the expiration of original patents, accelerating market penetration and product pipeline development[56] - The company's R&D strategy focuses on expanding from heparin-based products to oncology, immunomodulation, metabolic, digestive, and central nervous system diseases, while exploring nucleic acid-based drugs[54] - The company has 6 FDA-approved production lines with high automation and stable processes, significantly improving production efficiency and quality[57] - The company completed the acquisition of Meitheal, enhancing its overseas marketing channels and understanding of the US market[59] - Meitheal has established long-term stable relationships with GPOs, IDN/PNs, and the top three US wholesalers, supporting rapid growth in US sales[60] - The company has a complete sales channel and operational experience in the US market, with localized marketing strategies and deep integration with Meitheal[60] - The company is expanding its CDMO capabilities, attracting global and domestic pharmaceutical companies with its marketing and product development capabilities[61] - The company is optimizing its product structure and expanding production capacity through FDA-approved projects, enhancing its market position and competitiveness[58] - The company has 12 R&D projects in progress, with 7 projects in the stability testing phase and 5 projects under regulatory approval[64] - 7 drugs were approved by the US FDA during the reporting period, including Plerixafor Injection and Bupivacaine Hydrochloride Injection[64] - The company's US subsidiary achieved sales revenue exceeding RMB 800 million in the first half of 2023, a year-on-year increase of 49.70%[